VILMA M. VEGA, M.D.

CURRICULUM VITAE

MEDICAL LICENSE: Florida ME 0068013

MEDICAL EDUCATIONAL BACKGROUND

1993 – 1995	University of Miami, Jackson Memorial Hospital Miami, Florida. Fellowship in Infectious Disease
1990 – 1993	University of Miami, Jackson Memorial Hospital Miami, Florida. Internship and Residency, Internal Medicine
1986 – 1990	University of Illinois College of Medicine at Rockford Degree: Doctor of Medicine
1984 – 1986	Loyola University of Chicago Degree: Bachelor of Science

OTHER EDUCATIONAL BACKGROUND

2012 – 2016	Christian Family Church International Bible College Degree: Bachelor of Ministry
2015	American Council on Exercise (ACE) Degree: Certified Health and Wellness Coach
2015	Coach Approach Ministries Life and Executive Coaching
2015	National Council for Certified Personal Trainers Degree: Certified Personal Trainer
2015	Fellowship of Anti Aging and Regenerative Medicine Degree: Fellowship of Anti-Aging Medicine and Regenerative Medicine

CERTIFICATIONS

HIV Specialist (AAHIVS)

Infectious Disease Board Certified

Internal Medicine Board Eligible

Certified Personal Trainer from the National Council for Certified Personal Trainer June 2015

Certified Health and Wellness Coach from the American Council on Exercise August 2015

Diploma of Ministry 2014 Christian Family Church International Bible College

Bachelor of Ministry pending May 2016 Christian Family Church International Bible College

MEDICAL PROFESSIONAL EXPERIENCE

2003 – Present	Vega Consulting LLC – Sarasota, Florida – CEO / President
2012 – Present	Transition MD – Sarasota, Florida - CEO
1995 – Present:	Infectious Diseases Associates, Hospital and Office Consultants Sarasota, Florida
1995 – Present:	Preceptor for Medical, PharmD, and ARNP students from University of South Florida, Florida State University, and LECOM
1996.-.2012	Infectious Disease Associates Research Center-Clinical Research Director
2006.-.2008	Medical Director for GPSI Digital Mobile imaging

NONPROFIT PROFESSIONAL EXPERIENCE

Sep., 2015 - Present	Chief Medical Officer - Community Aids Network / Comprehensive Care Clinic
1995 – 2005	COMPREHENSIVE CARE CLINIC – Medical Director
2006-2011	HEARTS AFIRE INC. – CEO / Founder
2011 – Present	HEARTS AFIRE INC. – Executive Board Member / Chair of Grants and Projects Committee

STAFF AND ACADEMIC APPOINTMENTS

2008 – Present	Active Clinical Staff, Complex Care at Ridgelake Hospital, Sarasota, FL
2005 – Present	Preceptor, Florida State University College of Medicine, Sarasota, FL
2004 – Present:	Preceptor, University of Florida College of Pharmacy, Gainesville, FL
1995 – Present:	Active Clinical Staff, Sarasota Memorial Hospital, Sarasota, FL
1995 – Present	Active Clinical Staff, Doctors' Hospital of Sarasota, Sarasota, FL
1995 – Present	Consulting Clinical Staff, Healthsouth Hospital, Sarasota, FL
1995 – 2011	Consulting Clinical Staff, Venice Regional Medical Center, Venice, FL

MEDICAL SOCIETIES AND AFFILIATIONS

CMDA – Christian Medical and Dental Association

Infectious Diseases Society of America (IDSA)

American Academy of HIV Medicine (AAHIVM)

International Association of Physicians in AIDS Care (IAPAC)

AIDS Education and Training Center

Sarasota County Medical Society

HONORS AND AWARDS

FRIST Humanitarian Award from HCA Hospital 2008

Outstanding Community Leadership Award, Sarasota County Health Dept., 2006

Most Outstanding Clinical Instructor Award for a Resident, 1993

CIBA/Geigy Most Outstanding Community Service Award, 1988

Illinois Hospital Association Scholarship, 1988

Andrew Barr Female Medical Scholarship, 1986

ADVISORY BOARDS, CONSULTING COMMITTEES AND SPEAKERS BUREAUS

Abbott Laboratories

Pfizer / Agouron Pharmaceuticals

Ortho-Biotech

Bristol Meyers Squibb

Glaxo-Wellcome

Serono Pharmaceuticals

Merck Pharmaceuticals

Gilead Pharmaceuticals

Hoffman-LaRoche Pharmaceuticals

Boehringer – Ingelheim Pharmaceuticals

BTG Pharmaceuticals, Inc.

Johnson & Johnson / Tibotec / Virco

Monogram Biosciences, Inc.

CLINICAL RESEARCH (since 2000 only)

Merck Protocol MK023-00. Early Access of MK-0158 in Combination with an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients with Limited to No Treatment Options. November, 2006 – present.

Tibotec Pharmaceuticals, Ltd. Protocol TMC 125-C214. Early access of TMC 125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment Options. August, 2006 – present.

Pfizer Protocol A4001050. A Multicenter, Open-Label, Expanded Access Trial of Maraviroc. March, 2007 – present.

Gilead Sciences, Inc. Protocol GS-US-183-0130. A Phase 2 Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in combination with Other Antiretroviral Agents for The Treatment of HIV-Infected Subjects. June, 2007 – present.

GSK Protocol EPZ104057. A 96 Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Combination with Kaletra in Antiretroviral Naïve HIV-1 Infected Subjects. June, 2005 – present.

Theratechnologies, Inc. Protocol TH9507/III/LIPO/010. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg. Dose of TH9507, a Growth Hormone Releasing Factor analog, in HIV Patients with Excess of Abdominal Fat Accumulation. November, 2005 – June, 2007.

Gilead Sciences, Inc. Protocol GS-US-183-0105. A phase 2, randomized study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with A Background Antiretroviral Therapy. March, 2006 – June, 2007.

NeurogesX Protocol C119. A Multicenter, Randomized, Double-Blind, controlled Study of NGX-4010 For the Treatment of Painful HIV-Associated Neuropathy. April, 2006 – present.

Tibotec Pharmaceuticals, Ltd. Protocol TMC114-C226. Early Access of TMC114 in Combination with Low Dose Ritonavir (RTV) and Other Antiretrovirals (ARV's) in Highly Treatment Experienced HIV-1 Infected Subjects with Limited to No Treatment Options. April, 2006 – January, 2007.

Roche Protocol ML18018. A 12 Week, Prospective, Open-Label, Multicenter, Cohort Study to Assess HIV-Patient Quality of Life and Tolerability After Administration of Enfuvirtide-Containing HAART. (QUALITE). September, 2004 – October, 2005.

GlaxoSmithKline Protocol ESS101822. A Phase IIIB, Randomized, Open-Label, Multicenter, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of the Abacavir/Lamivudine Fixed –Dose Combination Tablet Administered Once Daily or the Separate Abacavir and Lamivudine Tablets Administered Twice-Daily, as Part of a Three or Four Drug Regimen, in Antiretroviral-Naïve HIV-1 Infected Subjects. August, 2004 – September, 2005.
Neurogesx Protocol C112. An International, Multicenter Randomized, Double-Blind, 12 week Controlled study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy. July, 2004 – October, 2005.

Serono Study 24380. A phase III, multicenter, randomized, double-blind, placebo controlled, Parallel group study of the safety and efficacy of Serostim® (mammalian cell-derived Recombinant human growth hormone r-hGH) in the treatment and maintenance of Human Immunodeficiency Virus Associated Adipose Redistribution Syndrome (HARS). June, 2004-April, 2006.

Roche Protocol NV17658. A Phase II, Open-Label, Randomized, Active-Controlled Study Comparing the efficacy and safety of once daily enfuvirtide dosing versus the currently Recommended twice daily dosing in HIV-1 infected treatment experienced patients. June, 2004 – June, 2006.

Roche Protocol NV17751. Observational Cohort Study of Pneumonia in Fuzeon-exposed and Non-exposed Patients. June, 2004 – present.

Solvay Pharmaceuticals. Protocol S1752101. A double-blind, randomized, parallel group, pilot Study of oral Dronabinol versus Placebo in the Prevention of Highly Active Antiretroviral Therapy (HAART) related Nausea and Vomiting. August, 2003 – November, 2005.

NARC Protocol No. 009/Savient Pharmaceuticals Protocol No. C0603. A Randomized, Double-blind, placebo controlled, multicenter dose ranging study to evaluate the safety of Prosaptide over 6 weeks of treatment for the relief of neuropathic pain associated with HIV-1. August, 2003 – May, 2005.

Gilead Pharmaceuticals. Protocol GS-01-934. A Phase 3, Randomized, Open-Label, Multicenter Study of the Treatment of Antiretroviral Naïve, HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination with Efavirenz. 2003.

Boehringer Ingelheim Pharmaceuticals, Inc. Protocol 1182.17. A long term open label rollover Trial assessing the safety and tolerance of combination Tipranavir and Ritonavir use in HIV-1 Infected subjects. October, 2003 – June, 2006.

Gilead Pharmaceuticals. IN-US-104-148. A Retrospective Analysis of the Tolerability of Tenofovir DF and Lopinavir/Ritonavir in 2 Groups of ARV Experienced HIV Infected Patients. Investigator initiated retrospective. Completed April, 2003.

Boehringer Ingelheim Pharmaceuticals, Inc. Protocol 1182.12 (RESIST I). Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug experienced patients. March, 2003 – June, 2006.

Boehringer Ingelheim Pharmaceuticals, Inc. Protocol 1182.51. An Open Label, Parallel Group Pharmokinetics Trial of Tipranavir/ Ritonavir (TPV/RTV) alone or in Combination with RTV boosted Saquinavir (SQV) Amprenavir (APV) or Lopinavir (LPV) plus an Optimised Background Regimen in Multiple ARV experienced Patients. March, 2003 – October, 2003.

Bristol Myers Squibb. Protocol AI424900. Atazanavir (BMS-232632) for HIV Infected Individuals: An Early Access Program. April, 2002 – September, 2003.

GlaxoSmithKline. Protocol APV30005. An Open Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects. March, 2002 – November, 2005.

OrthoBiotech. Protocol PR01-29-024. An Open Labeled Study to Evaluate the Effect of Every Other Week PROCRIT (Epoeitin alfa) Dosing on Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients. August, 2002 – June, 2004.

Schering Plough Research Institute. Protocol P00738. A Phase III Study of PEG Intron in Heavily Treatment Experienced HIV Infected Patients. February, 2002 – February, 2003.

GlaxoSmithKline. Protocol CNA30032. A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects who Developed a Hypersensitivity Following Treatment with Abacavir. November, 2001 – December, 2002.

Agouron Pharmaceuticals. Protocol AG1343-1205. Genotype Assisted Initial Nelfinavir Study. GAIN. January, 2002 – December, 2002.

InterMune, Inc. Protocol GIMAC-001. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon gamma-1b (IFN-y 1b) with Antimycobacterials in Previously Treated or Moderate-to-Severe Pulmonary Mycobacterium avium complex (MAC) November, 2001 – May, 2002.

Bristol-Myers Squibb. Protocol AI424-037. A Phase III Study Comparing the Antiviral Efficacy and Safety of Atazanavir with Nelfinavir; Each in Combination with Dual Nucleoside Therapy in HIV-Infected Subjects Who Have Failed a Regimen Not Containing a Protease Inhbitor. October, 2001 – February, 2002.

Glaxo SmithKline Protocol APV30002. A Randomized, Open Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908 / Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects. January, 2001 – October, 2002.

Schering Plough Research Institute. Protocol P01941. PEG-Intron HIV Treatment Protocol: A Substudy of P00737. May, 2001 – March, 2003.

Gilead Sciences Protocol GS-00-955. Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options. May, 2001 – November, 2001.

Abbott Laboratories Protocol M00-267. Performance of Lopinavir/Ritonavir as an Alternative Treatment Option (PLATO). May, 2001 – July, 2002.

OrthoBiotech Protocol PR 99-30-033. An Open Label, Randomized, Parallel Group Study Comparing the Effectiveness of PROCRIT (epoetin alfa) Administered Once Weekly Versus Standard of Care in Hepatitis C / HIV Co-infected Patients Treated with Combination Ribavirin / Interferon. September, 2000 – January, 2003.

Hepatitis Resource Network. HRN 003. PEG-Interferon alfa-2b + Ribavirin for Treatment of Patients with Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon alfa or Interferon alfa-2b + Ribavirin. August, 2000 – October 2002.

Triangle Pharmaceuticals, Inc. Protocol FTC-301. A Randomized, double-blind, Equivalence Trial comparing Emtricitabine to Stavudine within a Triple Drug Combination containing Didanosine and Efavirenz in Antiretroviral Drug Naïve HIV-1 Infected Patients. May, 2000-October, 2003.

Glaxo Wellcome Research and Development. Protocol ESS40002. A 96 week, Randomized, Open Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine + Lamivudine + Nelfinavir versus Abacavir + Combivir versus Combivir + Nelfinavir in HIV-1 Infected Subjects. May, 2000 – January, 2002.

Aventis Pharmaceuticals, Inc. Protocol SYN CMA-401. A Comparative, Parallel, Open Label, Randomized, Multicenter, Phase IIIB-IV Study of Synercid® I.V. 7.5 mg/kg q8h versus Vancomycin I.V. 1 g q12h (with a possible substitution of Vancomycin by a betalactam) for a maximum of 14 days in the Treatment of Nosocomial Staphylococcus spp. infections in About 500 Severely Ill inpatients. May, 2000 – March, 2001.

Schering Plough Research Institute. Protocol P00737. Antiretroviral Activity and Tolerability of PEG-Intron in HIV Infected Subjects Failing HAART. March, 2000 – March, 2001.

Hepatitis Resource Network Clinical Trials Group. HCV/HIV Coinfection Protocol version 2.1. A Multicenter, Randomized, Open Label Study of the Safety and Efficacy of Interferon Alfa-2b plus Ribavirin for the Treatment of HCV in HIV Infected Persons: Daily versus TIW Dosing. March, 2000 – September, 2001.

Agouron Pharmaceuticals, Inc. Protocol AG1549-509. A Phase II, Single-Blind, Randomized, Placebo-controlled Study of Capravirine (AG1549) in combination with Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen. March, 2000 – December, 2001.

Agouron Pharmaceuticals, Inc. Protocol AG1549-503. A Phase II Open Label Study of AG1549 in Combination with Other Antiretroviral Agents in Treatment Naïve HIV Infected Patients. January, 2000 – December, 2001.

SPEAKING ENGAGEMENTS

Over 100 US speaking engagements for medical speakers bureaus from 1995 – 2010

MERCK Pharmaceuticals Speaker's Bureau, August 2014 – Present

International Medical Speaking and Teaching Engagements:

University of Lima, Peru, "International Medicine and HIV", 2007

Christian Counselor College, Accra, Ghana, "HIV diagnosis and treatment", 2007

University of Gulu, Uganda, School of Clinical Officers "Primary HIV", 2008

University of Gulu, Uganda, School of Clinical Officers "HIV", "Tuberculosis", "Faith and HIV", 2009

KIMS College in Andrah Pradesh—Medical School, Nursing School, Paramedica—"Primary HIV", 2009

Christian Counselor College, Accra, Ghana, "International Medicine", 2010

Motivational Speaking Engagements:

American Business Women's Association, April 2012, "Making a Global Difference Through Your Life and Business"

William Wallace Memorial Baptist Church, June 2012, "Making a Difference Through Missions"

Christian Family Church Bible College Leadership Seminar – Moderator/Director, November 2012

Christian Family Church Sarasota, June 2013, "Blueprint to the Balanced Life"

Sarasota Daniel Plan, 2014, 7-week Faith Based Health and Wellness Community Outreach– Moderator / Director

Hearts Afire Annual Benefit – Keynote Speaker, February 22, 2014, "Living a Life Greater than Yourself"

Harvest Preparation International Annual Conference, March 18-19, 2014, "The Importance of Loving Yourself as part of the Blueprint to the Balanced Life"

Christian Family Church, May 25, 2014, "Faith through Discouragement"

The Harvest School of Miracles, July 3, 2014, "Faith, Miracles, and Medicine"

St. Leo University, September 2, 2015, "Principles of Leadership"

MEDIA

Infectious Disease Medical Appearances on ABC Suncoast Channel 7 News and SNN News, 1995 – Present

Appearances on Univision Medical News, 1994 and 2009

Appearances on WUSF Public Television and Radio, 2006-2015 – Influenza and HIV/AIDS

Trinity Broadcasting Network (TBN), 2015 – Medical Correspondent – "Mind, Body, Spirit"

LANGUAGES

Fluent English and Spanish; limited French and Creole